Hypertension reducing composition

Abstract

A composition effective to relax smooth muscles in an individual in an altered state is described. The composition includes a dosage of GABA or GABA-a analogue, and a dosage of at least one of an ACE inhibitor and an ARB combined with the dosage of GABA or GABA-a analogue into a deliverable form.

Having fully described the invention in such clear and concise terms as to enable those skilled in the art to understand and practice the same, the invention claimed is: 
     
         1 - 10 . (canceled) 
     
     
         11 . A method of relaxing smooth muscles in an individual having GABA receptors expressed in the individual's smooth muscles and endothelium, the method comprising the steps of:
 providing a composition of a dosage of GABA or GABA-a analogue and a dosage of at least one of an ACE inhibitor and a ARB combined into a deliverable form;   delivering the composition to an individual's circulatory system;   reducing the level of angiotensin II in the individual through the action of the dosage of the at least one of the ACE inhibitor and the ARB during a period of time; and   activating the GABA receptors through the action of the GABA or GABA-a analog during the period of time to promote production and release of smooth muscle relaxing substances by the activation of the GABA-a receptors.   
     
     
         12 . A method as claimed in  claim 11  wherein the step of providing a deliverable form of the composition includes providing the composition in one of tablets, capsules and IVs. 
     
     
         13 . A method as claimed in  claim 11  wherein the step of providing a deliverable form of the composition includes providing the composition as a tablet including the GABA or GABA-a analog in time release form. 
     
     
         14 . A method as claimed in  claim 11  wherein the step of providing a deliverable form of the composition includes providing the composition as a capsule including the GABA or GABA-a analog in time release form. 
     
     
         15 . A method as claimed in  claim 11  wherein the GABA or GABA-a analog dose is in the range of 1 mg/day to 10 gms/day, and at least one of the ACE-I dose being in the range of 1 mg/day to 450 mgs/day and the ARB dose being in the range of 1 mg/day to 1000 mg/day. 
     
     
         16 . A method as claimed in  claim 11  wherein activating the GABA receptors through the action of the GABA or GABA-a analog during the period of time includes delivering the GABA or GABA-a analog in a time release manner.